What is the recommended dosage of tizanidine (Zanaflex) for adults?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 14, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Tizanidine Dosage for Adults

Start tizanidine at 2-4 mg orally as a single dose, with gradual titration in 2-4 mg increments every 3-7 days to achieve optimal spasticity control, up to a maximum of 36 mg per day divided into three doses. 1

Initial Dosing

  • Begin with 4 mg orally as a single dose, as doses less than 8 mg have limited efficacy data but the dose-related adverse effects make starting at 4 mg prudent 1
  • For older adults or those with persistent pain, start at 2 mg up to three times daily to minimize sedation, hypotension, and cognitive effects 2
  • The effect peaks at 1-2 hours and dissipates between 3-6 hours after administration 1

Dose Titration

  • Increase gradually in 2-4 mg steps to achieve satisfactory reduction of muscle tone at a tolerated dose 1
  • Titration should occur over 2-4 weeks due to wide interpatient variability in effective plasma concentrations 3
  • Doses can be repeated at 6-8 hour intervals as needed, up to three doses in 24 hours 1

Maximum Dosing

  • Total daily dose should not exceed 36 mg 1
  • Single doses exceeding 8 mg and daily doses exceeding 24 mg have limited clinical experience 1
  • There is essentially no experience with repeated single daytime doses greater than 12 mg 1
  • In clinical trials, dosages of 2-36 mg/day have been used, with only 21% of patients able to reach the maximum 36 mg daily dose 3, 4

Special Populations

Older Adults (≥65 years)

  • Limit to 2 mg up to three times daily (maximum 6 mg/day initially) 2
  • Older persons rarely tolerate doses greater than 30-40 mg per day 2
  • Monitor closely for muscle weakness, urinary dysfunction, cognitive effects, sedation, and orthostasis 2

Hepatic or Renal Impairment

  • Avoid tizanidine in patients with hepatic or renal dysfunction due to significant sedative and hypotensive effects 2
  • Dose reduction and monitoring are recommended for both hepatic and renal impairment 2

Administration Considerations

Food Effects

  • Food has complex effects on tizanidine pharmacokinetics that may result in clinically significant differences when switching between fed and fasted states 1
  • These changes may result in increased adverse events or delayed/more rapid onset of activity 1
  • Maintain consistent administration relative to meals to avoid variability 1

Perioperative Management

  • Continue tizanidine preoperatively including the day of surgery 2
  • Abrupt discontinuation risks withdrawal symptoms including rebound tachycardia, hypertension, and hypertonia 2
  • If discontinuation is necessary in long-term users, taper the dose slowly 2

Clinical Efficacy Data

  • In stroke-related spasticity, tizanidine demonstrated significant improvement with mean daily doses of 18 mg (range 2-24 mg) over 16 weeks 4
  • For chronic daily headache prophylaxis, mean effective dose was 18 mg/day (median 20 mg, range 2-24 mg) divided into three doses 5
  • Antispastic efficacy shows reduction in muscle tone scores of 21-37% versus 4-9% for placebo 3
  • In back pain with muscle spasm, initial pain relief occurred on day 2 of treatment with complete relief after 4 days using the lowest recommended doses 6

Critical Safety Monitoring

Hypotension Risk

  • Two-thirds of patients taking 8 mg experience a 20% reduction in diastolic or systolic blood pressure within 1 hour of dosing 1
  • The hypotensive effect is dose-related and occurs with doses ≥2 mg 1
  • Monitor for bradycardia, orthostatic hypotension, lightheadedness, dizziness, and rarely syncope 1
  • Do not use with other α2-adrenergic agonists or concurrent antihypertensive therapy without extreme caution 1

Hepatotoxicity

  • Monitor aminotransferase levels during the first 6 months of treatment 1
  • Approximately 5% of patients develop liver function test elevations >3 times upper limit of normal 1
  • Three deaths associated with liver failure have been reported in postmarketing experience 1

Drug Interactions

  • Contraindicated with ciprofloxacin and fluvoxamine due to significantly reduced clearance 2
  • Significant hypotension, bradycardia, and sedation can occur with CYP1A2 inhibitors including oral contraceptives, acyclovir, amiodarone, verapamil, cimetidine, and famotidine 2
  • Increased risk of prolonged QTc when prescribed with methadone 2

Common Adverse Effects

  • Somnolence/drowsiness (47-62% of patients) 3, 4
  • Dry mouth (23-80% of patients) 3, 4
  • Dizziness (24-32% of patients) 4, 5
  • Asthenia (19% of patients) 5
  • Unlike baclofen, subjective muscle weakness is reported less frequently with tizanidine 3

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.